Selective estrogen receptor modulators bind to estrogen receptors in the cancer cells and block estrogen from helping cancer cells to grow. Tamoxifen (Soltamox®), raloxifene (Evista®), and toremifene (Fareston®) are SERMs used to treat estrogen receptor–positive breast cancer. All three hormonal therapy drugs are administered orally.
IN MEMORIAM: BCRF remembers its greatest champion—Leonard A. Lauder. 
Support research with a legacy gift. Sample, non-binding bequest language:
I give to the Breast Cancer Research Foundation, located in New York, NY, federal tax identification number 13-3727250, ________% of my total estate (or $_____).
Connect on Social
Connect on Social
Breast Cancer Research Foundation
28 West 44th Street, Suite 609, New York, NY 10036
General Office: 646-497-2600 | Toll Free: 1-866-346-3228
bcrf@bcrf.org | BCRF is a 501 (c)(3) | EIN: 13-3727250